Helicobacteriology update
Alfred Tay A C , Michael J Wise A B and Barry J Marshall A
+ Author Affiliations
- Author Affiliations
A The Marshall Centre for Infectious Diseases, Research and Training, University of Western Australia, Perth, WA 6009, Australia
B Department of Computer Science and Software Engineering, University of Western Australia, Perth, WA 6009, Australia
C Email: alfred.tay@uwa.edu.au
Microbiology Australia 42(2) 92-95 https://doi.org/10.1071/MA21025
Submitted: 12 March 2021 Accepted: 28 April 2021 Published: 21 May 2021
Journal Compilation © The Authors 2021 Open Access CC BY-NC-ND, published (by CSIRO Publishing) on behalf of the ASM
Abstract
Helicobacter pylori colonises the gastric mucosa and is associated with various gastric diseases, including stomach cancer. At least 1 million new cases of stomach cancer cases are reported annually, and it is the fifth top cancer-killer in the world. Although H. pylori can be eradicated by a combination of antibiotics, the treatment success rate is declining due to the rise of antibiotic resistance. The same antibiotic combination must not be prescribed repeatedly. Susceptibility guided precision medicine is the most effective strategy to combat antibiotic resistant H. pylori cases. In addition, maintaining a stomach pH ≥6 during the antibiotic treatment is an important factor to increase cure rates. The new type of acid blocker, P-CABs, have shown promising results in H. pylori treatment. Natural products may suppress the H. pylori growth or relieve the symptoms but have not been successful in solving the root of the problem. New combination therapies show promise and the dream of 100% cure of the infection with minimal side effects from treatment seems achievable. The next decade will see combination therapies with newer acid blockers in widespread use at reasonable cost.
References
[1] Labigne, A. and de Reuse, H. (1996) Determinants of Helicobacter pylori pathogenicity. Infect. Agents Dis. 5, 191–202.| 8884364PubMed |
[2] McColl, K.E. (1997) Helicobacter pylori: clinical aspects. J. Infect. 34, 7–13.
| Helicobacter pylori: clinical aspects.Crossref | GoogleScholarGoogle Scholar | 9120329PubMed |
[3] Marshall, B.J. and Warren, J.R. (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 323, 1311–1315.
| Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration.Crossref | GoogleScholarGoogle Scholar |
[4] Bray, F. et al. (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424.
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.Crossref | GoogleScholarGoogle Scholar | 30207593PubMed |
[5] (1994) Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7–14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 61, 1–241.
| 7715068PubMed |
[6] Moss, S.F. (2017) The clinical evidence linking Helicobacter pylori to gastric cancer. Cell. Mol. Gastroenterol. Hepatol. 3, 183–191.
| The clinical evidence linking Helicobacter pylori to gastric cancer.Crossref | GoogleScholarGoogle Scholar | 28275685PubMed |
[7] Tacconelli, E. et al. (2018) Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–327.
| Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis.Crossref | GoogleScholarGoogle Scholar | 29276051PubMed |
[8] Dang, B.N. and Graham, D.Y. (2017) Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat. Rev. Gastroenterol. Hepatol. 14, 383–384.
| Helicobacter pylori infection and antibiotic resistance: a WHO high priority?Crossref | GoogleScholarGoogle Scholar | 28465548PubMed |
[9] O’Mahony, R. et al. (2005) Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori. World J. Gastroenterol. 11, 7499–7507.
| Bactericidal and anti-adhesive properties of culinary and medicinal plants against Helicobacter pylori.Crossref | GoogleScholarGoogle Scholar | 16437723PubMed |
[10] Sari, Y.S. et al. (2008) H pylori: treatment for the patient only or the whole family? World J. Gastroenterol. 14, 1244–1247.
| H pylori: treatment for the patient only or the whole family?Crossref | GoogleScholarGoogle Scholar | 18300351PubMed |
[11] Windsor, H.M. et al. (2005) Prevalence of Helicobacter pylori in Indigenous Western Australians: comparison between urban and remote rural populations. Med. J. Aust. 182, 210–213.
| Prevalence of Helicobacter pylori in Indigenous Western Australians: comparison between urban and remote rural populations.Crossref | GoogleScholarGoogle Scholar | 15748129PubMed |
[12] Wise, M.J. et al. (2019) A longitudinal, population-level, big-data study of Helicobacter pylori-related disease across Western Australia. J. Clin. Med. 8, 1821.
| A longitudinal, population-level, big-data study of Helicobacter pylori-related disease across Western Australia.Crossref | GoogleScholarGoogle Scholar |
[13] Australian Institute of Health and Welfare (2020) Stomach cancer statistics. https://www.canceraustralia.gov.au/affected-cancer/cancer-types/stomach-cancer/stomach-cancer-statistics (accessed March 2021).
[14] Sung, H. et al. (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. , .
| Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.Crossref | GoogleScholarGoogle Scholar | 33538338PubMed |
[15] Higashi, H. et al. (2002) Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites. Proc. Natl. Acad. Sci. USA 99, 14428–14433.
| Biological activity of the Helicobacter pylori virulence factor CagA is determined by variation in the tyrosine phosphorylation sites.Crossref | GoogleScholarGoogle Scholar | 12391297PubMed |
[16] Olbermann, P. et al. (2010) A global overview of the genetic and functional diversity in the Helicobacter pylori cag pathogenicity island. PLoS Genet. 6, e1001069.
| A global overview of the genetic and functional diversity in the Helicobacter pylori cag pathogenicity island.Crossref | GoogleScholarGoogle Scholar | 20808891PubMed |
[17] Censini, S. et al. (1996) cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc. Natl. Acad. Sci. USA 93, 14648–14653.
| cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors.Crossref | GoogleScholarGoogle Scholar | 8962108PubMed |
[18] Posselt, G. et al. (2013) The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis. Cell Commun. Signal. 11, 77.
| The functional interplay of Helicobacter pylori factors with gastric epithelial cells induces a multi-step process in pathogenesis.Crossref | GoogleScholarGoogle Scholar | 24099599PubMed |
[19] Umehara, S. et al. (2003) Effects of Helicobacter pylori CagA protein on the growth and survival of B lymphocytes, the origin of MALT lymphoma. Oncogene 22, 8337–8342.
| Effects of Helicobacter pylori CagA protein on the growth and survival of B lymphocytes, the origin of MALT lymphoma.Crossref | GoogleScholarGoogle Scholar | 14614457PubMed |
[20] Murata-Kamiya, N. et al. (2007) Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells. Oncogene 26, 4617–4626.
| Helicobacter pylori CagA interacts with E-cadherin and deregulates the beta-catenin signal that promotes intestinal transdifferentiation in gastric epithelial cells.Crossref | GoogleScholarGoogle Scholar | 17237808PubMed |
[21] Marshall, B.J. et al. (1987) Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion 37, 16–30.
| Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis.Crossref | GoogleScholarGoogle Scholar | 3622946PubMed |
[22] McNicholl, A.G. et al. (2020) Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin. Gastroenterol. Hepatol. 18, 89–98.
| Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients.Crossref | GoogleScholarGoogle Scholar | 30978536PubMed |
[23] Kumar, S. et al. (2020) Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study. Gastroenterology 158, 527–536 e7.
| Risk factors and incidence of gastric cancer after detection of Helicobacter pylori infection: a large cohort study.Crossref | GoogleScholarGoogle Scholar | 31654635PubMed |
[24] Leung, W.K. et al. (2018) Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals. Gastroenterology 155, 67–75.
| Effects of Helicobacter pylori treatment on incidence of gastric cancer in older individuals.Crossref | GoogleScholarGoogle Scholar | 29550592PubMed |
[25] Choi, I.J. et al. (2020) Family history of gastric cancer and Helicobacter pylori treatment. N. Engl. J. Med. 382, 427–436.
| Family history of gastric cancer and Helicobacter pylori treatment.Crossref | GoogleScholarGoogle Scholar | 31995688PubMed |
[26] Graham, D.Y. (1997) The only good Helicobacter pylori is a dead Helicobacter pylori. Lancet 350, 70–71.
| The only good Helicobacter pylori is a dead Helicobacter pylori.Crossref | GoogleScholarGoogle Scholar | 9217742PubMed |
